8-K
Karyopharm Therapeutics Inc. (KPTI)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 21, 2021
Karyopharm Therapeutics Inc.
(Exact Name of Registrant as Specified in Charter)
| Delaware | 001-36167 | 26-3931704 |
|---|---|---|
| (State or Other Jurisdiction<br> <br>of Incorporation) | (Commission<br> <br>File Number) | (IRS Employer<br> <br>Identification No.) |
| 85 Wells Avenue, 2nd Floor<br> <br>Newton, Massachusetts | 02459 | |
| --- | --- | |
| (Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (617) 658-0600
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading<br> <br>Symbol(s) | Name of each exchange<br> <br>on which registered |
|---|---|---|
| Common Stock, $0.0001 par value | KPTI | Nasdaq Global Select Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.07. | Submission of Matters to a Vote of Security Holders. |
|---|
Karyopharm Therapeutics Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders on May 21, 2021 (the “Annual Meeting”). The following is a summary of the matters voted on at the Annual Meeting.
| 1. | The Company’s stockholders elected Deepika Pakianathan, Ph.D., Richard Paulson, M.B.A. and Chen Schor, M.B.A., C.P.A. as Class II directors, each to serve on the board of directors of the Company for a three-year term until the 2024 annual meeting of stockholders and until their resignation or removal or until their successors are duly elected and qualified. The results of the stockholders’ vote with respect to the election of such Class II directors were as follows: | |||||
|---|---|---|---|---|---|---|
| Votes For | Votes Withheld | Broker Non-Votes | ||||
| --- | --- | --- | --- | --- | --- | --- |
| Deepika Pakianathan, Ph.D. | 33,788,086 | 7,286,491 | 19,059,473 | |||
| Richard Paulson, M.B.A. | 38,108,285 | 2,966,292 | 19,059,473 | |||
| Chen Schor, M.B.A., C.P.A. | 38,165,000 | 2,909,577 | 19,059,473 | |||
| 2. | The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s proxy statement for the Annual Meeting. The results of the stockholders’ vote with respect to such approval were as follows: | |||||
| --- | --- | |||||
| Votes For | Votes Against | Votes Abstaining | Broker Non-Votes | |||
| --- | --- | --- | --- | |||
| 37,981,962 | 2,969,679 | 122,936 | 19,059,473 | |||
| 3. | The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021. The results of the stockholders’ vote with respect to such ratification were as follows: | |||||
| --- | --- | |||||
| Votes For | Votes Against | Votes Abstaining | ||||
| --- | --- | --- | ||||
| 56,309,791 | 902,442 | 2,921,817 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| KARYOPHARM THERAPEUTICS INC. | ||
|---|---|---|
| Date: May 24, 2021 | By: | /s/ Michael Mano |
| Michael Mano | ||
| Senior Vice President, General Counsel and Secretary |